Shanghai Minority Interest vs Net Income From Continuing Ops Analysis

601607 Stock

20.15 0.32 1.61%

Shanghai Pharmaceuticals financial indicator trend analysis is much more than just breaking down Shanghai Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Shanghai Pharmaceuticals is a good investment. Please check the relationship between Shanghai Pharmaceuticals Minority Interest and its Net Income From Continuing Ops accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Minority Interest vs Net Income From Continuing Ops

Minority Interest vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Shanghai Pharmaceuticals Minority Interest account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Shanghai Pharmaceuticals' Minority Interest and Net Income From Continuing Ops is -0.17. Overlapping area represents the amount of variation of Minority Interest that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Shanghai Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Shanghai Pharmaceuticals' Minority Interest and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Minority Interest of Shanghai Pharmaceuticals Holding are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Minority Interest i.e., Shanghai Pharmaceuticals' Minority Interest and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.17

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Minority Interest

Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Shanghai Pharmaceuticals Holding whose combined shares represent less than 50% of the total outstanding shares issued by Shanghai Pharmaceuticals have a minority interest in Shanghai Pharmaceuticals.

Net Income From Continuing Ops

Most indicators from Shanghai Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Shanghai Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of January 31, 2025, Selling General Administrative is expected to decline to about 6.7 B. In addition to that, Tax Provision is expected to decline to about 1.6 B

	2022	2023	2024	2025 (projected)
Operating Income	8.8B	9.6B	11.0B	11.5B
Total Revenue	232.0B	260.3B	299.3B	314.3B

Operating Income Total Revenue

Shanghai Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Other Liab	Good Will	Net Tangible Assets	Other Stockholder Equity	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Total Current Assets	Short Term Debt
Total Assets		0.79	1.0	0.99	0.99	1.0	0.98	0.74	0.74	1.0	0.91	1.0	0.25	1.0	0.76	0.85	0.98	0.97	0.83	0.86	-0.46	0.57	0.88	0.9	0.9	0.83
Other Current Liab	0.79		0.79	0.72	0.83	0.78	0.74	0.81	0.74	0.81	0.87	0.77	0.74	0.81	0.62	0.6	0.89	0.85	0.9	0.7	-0.72	0.92	0.84	0.78	0.68	0.89
Total Current Liabilities	1.0	0.79		0.98	0.99	0.99	0.97	0.73	0.72	1.0	0.91	0.99	0.25	1.0	0.74	0.83	0.98	0.97	0.82	0.87	-0.45	0.58	0.89	0.91	0.9	0.83
Total Stockholder Equity	0.99	0.72	0.98		0.97	0.99	0.99	0.69	0.67	0.98	0.84	0.99	0.17	0.98	0.8	0.91	0.95	0.94	0.78	0.84	-0.36	0.46	0.83	0.86	0.87	0.76
Retained Earnings	0.99	0.83	0.99	0.97		0.99	0.96	0.77	0.75	0.99	0.9	0.99	0.34	0.99	0.74	0.82	0.99	0.99	0.86	0.87	-0.48	0.62	0.9	0.91	0.89	0.86
Accounts Payable	1.0	0.78	0.99	0.99	0.99		0.97	0.76	0.74	1.0	0.88	1.0	0.28	0.99	0.75	0.87	0.97	0.96	0.83	0.84	-0.45	0.55	0.86	0.89	0.88	0.81
Cash	0.98	0.74	0.97	0.99	0.96	0.97		0.66	0.65	0.96	0.86	0.97	0.17	0.97	0.83	0.91	0.94	0.94	0.77	0.83	-0.38	0.49	0.82	0.85	0.87	0.75
Other Assets	0.74	0.81	0.73	0.69	0.77	0.76	0.66		0.84	0.78	0.77	0.76	0.62	0.76	0.41	0.6	0.81	0.75	0.81	0.57	-0.78	0.72	0.8	0.76	0.62	0.82
Long Term Debt	0.74	0.74	0.72	0.67	0.75	0.74	0.65	0.84		0.76	0.83	0.76	0.43	0.76	0.43	0.52	0.76	0.72	0.8	0.58	-0.8	0.72	0.74	0.79	0.67	0.82
Net Receivables	1.0	0.81	1.0	0.98	0.99	1.0	0.96	0.78	0.76		0.92	0.99	0.3	1.0	0.73	0.83	0.98	0.97	0.85	0.86	-0.5	0.61	0.9	0.91	0.89	0.85
Short Term Investments	0.91	0.87	0.91	0.84	0.9	0.88	0.86	0.77	0.83	0.92		0.89	0.38	0.93	0.66	0.64	0.93	0.9	0.87	0.81	-0.71	0.78	0.88	0.89	0.86	0.89
Inventory	1.0	0.77	0.99	0.99	0.99	1.0	0.97	0.76	0.76	0.99	0.89		0.26	0.99	0.75	0.87	0.97	0.95	0.83	0.83	-0.47	0.55	0.86	0.9	0.88	0.82
Other Current Assets	0.25	0.74	0.25	0.17	0.34	0.28	0.17	0.62	0.43	0.3	0.38	0.26		0.28	0.1	0.16	0.42	0.37	0.6	0.18	-0.62	0.79	0.43	0.31	0.14	0.55
Total Liab	1.0	0.81	1.0	0.98	0.99	0.99	0.97	0.76	0.76	1.0	0.93	0.99	0.28		0.74	0.82	0.98	0.97	0.84	0.87	-0.49	0.61	0.9	0.92	0.9	0.85
Intangible Assets	0.76	0.62	0.74	0.8	0.74	0.75	0.83	0.41	0.43	0.73	0.66	0.75	0.1	0.74		0.84	0.73	0.72	0.6	0.67	-0.21	0.37	0.57	0.58	0.66	0.5
Common Stock	0.85	0.6	0.83	0.91	0.82	0.87	0.91	0.6	0.52	0.83	0.64	0.87	0.16	0.82	0.84		0.8	0.78	0.66	0.63	-0.25	0.3	0.62	0.66	0.67	0.55
Property Plant Equipment	0.98	0.89	0.98	0.95	0.99	0.97	0.94	0.81	0.76	0.98	0.93	0.97	0.42	0.98	0.73	0.8		0.99	0.88	0.87	-0.55	0.71	0.92	0.91	0.87	0.9
Other Liab	0.97	0.85	0.97	0.94	0.99	0.96	0.94	0.75	0.72	0.97	0.9	0.95	0.37	0.97	0.72	0.78	0.99		0.85	0.88	-0.47	0.66	0.92	0.91	0.88	0.88
Good Will	0.83	0.9	0.82	0.78	0.86	0.83	0.77	0.81	0.8	0.85	0.87	0.83	0.6	0.84	0.6	0.66	0.88	0.85		0.79	-0.72	0.74	0.91	0.91	0.84	0.96
Net Tangible Assets	0.86	0.7	0.87	0.84	0.87	0.84	0.83	0.57	0.58	0.86	0.81	0.83	0.18	0.87	0.67	0.63	0.87	0.88	0.79		-0.3	0.48	0.91	0.9	0.96	0.82
Other Stockholder Equity	-0.46	-0.72	-0.45	-0.36	-0.48	-0.45	-0.38	-0.78	-0.8	-0.5	-0.71	-0.47	-0.62	-0.49	-0.21	-0.25	-0.55	-0.47	-0.72	-0.3		-0.8	-0.58	-0.58	-0.42	-0.72
Deferred Long Term Liab	0.57	0.92	0.58	0.46	0.62	0.55	0.49	0.72	0.72	0.61	0.78	0.55	0.79	0.61	0.37	0.3	0.71	0.66	0.74	0.48	-0.8		0.68	0.59	0.46	0.77
Long Term Investments	0.88	0.84	0.89	0.83	0.9	0.86	0.82	0.8	0.74	0.9	0.88	0.86	0.43	0.9	0.57	0.62	0.92	0.92	0.91	0.91	-0.58	0.68		0.96	0.91	0.96
Short Long Term Debt	0.9	0.78	0.91	0.86	0.91	0.89	0.85	0.76	0.79	0.91	0.89	0.9	0.31	0.92	0.58	0.66	0.91	0.91	0.91	0.9	-0.58	0.59	0.96		0.96	0.95
Total Current Assets	0.9	0.68	0.9	0.87	0.89	0.88	0.87	0.62	0.67	0.89	0.86	0.88	0.14	0.9	0.66	0.67	0.87	0.88	0.84	0.96	-0.42	0.46	0.91	0.96		0.86
Short Term Debt	0.83	0.89	0.83	0.76	0.86	0.81	0.75	0.82	0.82	0.85	0.89	0.82	0.55	0.85	0.5	0.55	0.9	0.88	0.96	0.82	-0.72	0.77	0.96	0.95	0.86

Click cells to compare fundamentals

Shanghai Pharmaceuticals Account Relationship Matchups

Shanghai Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	149.2B	163.4B	198.1B	212.0B	243.8B	256.0B
Other Current Liab	9.5B	9.7B	6.4B	6.3B	7.2B	7.6B
Total Current Liabilities	88.1B	91.8B	110.7B	122.4B	140.7B	147.8B
Total Stockholder Equity	45.4B	49.4B	67.1B	68.5B	78.8B	82.7B
Retained Earnings	26.9B	30.6B	34.6B	33.8B	38.9B	40.8B
Accounts Payable	37.8B	42.0B	51.6B	54.6B	62.8B	66.0B
Cash	22.3B	22.4B	27.4B	30.5B	35.1B	36.9B
Other Assets	2.9B	5.7B	2.8B	3.0B	3.5B	3.7B
Long Term Debt	1.2B	7.2B	6.3B	5.8B	6.7B	7.0B
Net Receivables	52.7B	58.1B	66.8B	72.9B	83.9B	88.1B
Inventory	24.1B	27.1B	34.5B	36.6B	42.1B	44.2B
Other Current Assets	4.3B	4.2B	1.4B	1.4B	1.6B	1.5B
Total Liab	94.4B	104.4B	120.1B	131.6B	151.4B	159.0B
Intangible Assets	5.4B	6.3B	6.6B	6.4B	7.3B	7.7B
Property Plant Equipment	10.6B	13.1B	14.6B	15.8B	18.2B	19.1B
Other Liab	2.1B	2.7B	3.6B	4.0B	4.5B	4.8B
Good Will	11.3B	11.2B	11.3B	11.4B	13.1B	7.3B
Net Tangible Assets	23.6B	26.9B	28.8B	32.1B	36.9B	28.6B
Other Stockholder Equity	(492.6M)	(542.2M)	(265.4M)	(144.4M)	(130.0M)	(136.5M)
Deferred Long Term Liab	606.4M	639.1M	688.3M	342.6M	394.0M	504.8M
Short Long Term Debt	20.1B	22.5B	27.8B	35.6B	40.9B	21.0B
Total Current Assets	107.6B	116.5B	149.5B	162.4B	186.8B	111.5B
Non Current Assets Total	41.6B	46.9B	48.6B	49.5B	57.0B	42.3B
Non Currrent Assets Other	12.6B	856.9M	443.8M	440.7M	506.8M	481.5M
Non Current Liabilities Total	6.3B	12.5B	9.4B	9.3B	10.7B	9.9B
Non Current Liabilities Other	170.4M	566.1M	257.3M	250.1M	287.7M	274.1M
Net Invested Capital	66.7B	79.0B	101.1B	109.9B	126.4B	86.3B
Net Working Capital	19.4B	24.7B	38.8B	40.1B	46.1B	29.9B
Property Plant And Equipment Net	14.2B	15.4B	16.2B	17.9B	20.6B	16.8B
Capital Lease Obligations	1.5B	1.4B	1.3B	1.6B	1.8B	1.5B
Property Plant And Equipment Gross	21.0B	22.9B	16.2B	17.9B	16.1B	15.5B

Currently Active Assets on Macroaxis

F	Ford Motor
GM	General Motors
S	SentinelOne
GOOG	Alphabet Inc Class C
WD	Walker Dunlop

Other Information on Investing in Shanghai Stock

Balance Sheet is a snapshot of the financial position of Shanghai Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Shanghai Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Shanghai Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Shanghai currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shanghai Minority Interest vs Net Income From Continuing Ops Analysis

Minority Interest vs Net Income From Continuing Ops

Minority Interest vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Minority Interest

Net Income From Continuing Ops

Shanghai Pharmaceuticals fundamental ratios Correlations

Shanghai Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Shanghai Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Assets
Inventory	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Assets
Net Receivables	+ 1.0	Total Current Liabilities

Deferred Long Term Liab	- 0.8	Other Stockholder Equity
Other Stockholder Equity	- 0.8	Long Term Debt
Other Stockholder Equity	- 0.78	Other Assets
Short Term Debt	- 0.72	Other Stockholder Equity
Other Stockholder Equity	- 0.72	Good Will
Other Stockholder Equity	- 0.72	Other Current Liab